Last reviewed · How we verify
Xenetix-CT perfusion imaging
Xenetix is an iodinated contrast medium that enhances visualization of blood perfusion in tissues during CT imaging by increasing radiodensity in vascular and tissue compartments.
Xenetix is an iodinated contrast medium that enhances visualization of blood perfusion in tissues during CT imaging by increasing radiodensity in vascular and tissue compartments. Used for CT perfusion imaging of the brain for acute stroke evaluation, CT perfusion imaging of the heart for myocardial ischemia assessment, CT perfusion imaging of solid organs for tumor characterization and tissue viability assessment.
At a glance
| Generic name | Xenetix-CT perfusion imaging |
|---|---|
| Sponsor | Guerbet |
| Drug class | Iodinated contrast medium |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Xenetix contains iopamidol, a non-ionic iodinated contrast agent that distributes through the vasculature and extracellular space. The iodine atoms attenuate X-rays, creating enhanced contrast between perfused and non-perfused tissues on CT scans. This allows quantitative assessment of regional blood flow and tissue perfusion in organs such as the brain, heart, and lungs.
Approved indications
- CT perfusion imaging of the brain for acute stroke evaluation
- CT perfusion imaging of the heart for myocardial ischemia assessment
- CT perfusion imaging of solid organs for tumor characterization and tissue viability assessment
Common side effects
- Contrast-induced nephropathy
- Allergic reaction (mild to moderate)
- Nausea and vomiting
- Flushing and warmth sensation
- Thyroid dysfunction (iodine-related)
Key clinical trials
- Hepatic Xenetix-CT Perfusion (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |